ATE273393T1 - Modifizierter faktor-vii - Google Patents

Modifizierter faktor-vii

Info

Publication number
ATE273393T1
ATE273393T1 AT92907393T AT92907393T ATE273393T1 AT E273393 T1 ATE273393 T1 AT E273393T1 AT 92907393 T AT92907393 T AT 92907393T AT 92907393 T AT92907393 T AT 92907393T AT E273393 T1 ATE273393 T1 AT E273393T1
Authority
AT
Austria
Prior art keywords
vii
modified
modified factor
factor vii
factor
Prior art date
Application number
AT92907393T
Other languages
English (en)
Inventor
Kathleen L Berkner
Lars Christian Petersen
Original Assignee
Zymogenetics Inc
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Novo Nordisk As filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE273393T1 publication Critical patent/ATE273393T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT92907393T 1991-02-28 1992-02-28 Modifizierter faktor-vii ATE273393T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292091A 1991-02-28 1991-02-28
PCT/US1992/001636 WO1992015686A1 (en) 1991-02-28 1992-02-28 Modified factor vii

Publications (1)

Publication Number Publication Date
ATE273393T1 true ATE273393T1 (de) 2004-08-15

Family

ID=24659758

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92907393T ATE273393T1 (de) 1991-02-28 1992-02-28 Modifizierter faktor-vii

Country Status (8)

Country Link
EP (2) EP0575464B1 (de)
JP (2) JP3459416B2 (de)
AT (1) ATE273393T1 (de)
AU (1) AU672357B2 (de)
CA (1) CA2103546C (de)
DE (1) DE69233398D1 (de)
HU (1) HU218890B (de)
WO (1) WO1992015686A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
PT699075E (pt) * 1993-05-21 2002-05-31 Novo Nordisk As Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
EP1005361B1 (de) 1997-07-18 2010-01-06 Novo Nordisk Health Care AG VERWENDUNG VON FVIIa ODER FVIIAi ZUR BEHANDLUNG VON ENDOTHELIALER FEHLFUNKTION BZW ZUR INHIBIERUNG DER ANGIOGENESE
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
ATE509028T1 (de) 1999-03-15 2011-05-15 Novo Nordisk As Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1188770A4 (de) * 1999-06-14 2004-03-24 Fujimori Kogyo Co Ltd Substanz, welche an das substrat eines aktivierten blutgerinnungsfaktors bindet, verfahren zur herstellung des substrats
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
AU9165201A (en) 2000-10-02 2002-04-15 Novo Nordisk As Factor vii glycoforms
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
RU2003134701A (ru) * 2001-05-02 2005-03-27 Ново Нордиск А/С (DK) Модифицированный fvii при лечении ards
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
BR0309576A (pt) 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
AU2003223925A1 (en) * 2002-05-03 2003-11-17 Novo Nordisk A/S Stabilised solid compositions of modified factor vii
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1615945B1 (de) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
BRPI0409936A (pt) 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
DE602004025576D1 (de) 2003-06-19 2010-04-01 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
ATE547114T1 (de) 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005016365A2 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1711513B1 (de) 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration von faktor vii lösungen zur entfernung von viren
ES2676644T3 (es) 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1924689B1 (de) 2005-09-01 2014-08-13 Novo Nordisk Health Care AG Reinigung von faktor-vii-polypeptiden mittels hydrophober interaktionschromatografie
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
AU2008345231B2 (en) 2007-12-27 2014-09-11 Takeda Pharmaceutical Company Limited Cell culture processes
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
ES2966234T3 (es) 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Composiciones de hemoglobina
US20150259665A1 (en) 2012-10-15 2015-09-17 Novo Nordisk Health Care Ag Factor vii conjugates
ES2856968T3 (es) 2016-01-15 2021-09-28 Rigshospitalet Adquisición de imágenes de TEP cuantitativas de la expresión de factor tisular usando factor VII inhibido en el punto activo y marcado con 18F
WO2018091058A1 (en) 2016-11-17 2018-05-24 Rigshospitalet 177-lu labeled active site inhibited factor vii

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2074839C (en) * 1990-01-29 2000-11-14 Kathleen L. Berkner Modified factor vii anticoagulant proteins

Also Published As

Publication number Publication date
HU9302438D0 (en) 1993-12-28
CA2103546A1 (en) 1992-08-29
JPH06504678A (ja) 1994-06-02
HUT71572A (en) 1995-12-28
JP2003289890A (ja) 2003-10-14
AU672357B2 (en) 1996-10-03
EP1479395A1 (de) 2004-11-24
JP3459416B2 (ja) 2003-10-20
AU1449892A (en) 1992-10-06
EP0575464B1 (de) 2004-08-11
DE69233398D1 (de) 2004-09-16
EP0575464A1 (de) 1993-12-29
WO1992015686A1 (en) 1992-09-17
CA2103546C (en) 2002-10-01
HU218890B (hu) 2000-12-28

Similar Documents

Publication Publication Date Title
DE69233398D1 (de) Modifizierter faktor-vii
DK0699075T3 (da) Modificeret faktor VII
MX9702951A (es) Factor vii modificado.
KR950702418A (ko) 레트로바이러스성 프로테아제 억제 화합물(Retroviral protease inhibiting compounds)
FI935675A0 (fi) Pyrazolopyrimidiner
BR9709661A (pt) Processos para inibir a formação de trombos em um paciente, para manter ou melhorar a patência vascular em um paciente, para evitar ou minimizar o dano miocardìaco associado com reperfusão pós-isquêmica em um indivìduo, e, para melhorar o fluxo sanguìneo no miocárdio regional durante a reperfusão pós-isquêmica em um indivìduo, e, uso do fator vii
DE69304955D1 (de) Behandlung von neurodegenerativen Erkrankungen
ATE175876T1 (de) Verkürzter gewebsfaktor und fviia oder fvii zur aktivierung der blutgerinnung
DE68913132D1 (de) Hirudin und Aktivator des Plasminogens enthaltende pharmazeutische wirksame Verbindung.
SE8704298D0 (sv) Compounds for use in therapy
DK1030836T3 (da) Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet
NO864443L (no) Fremgangsmaate for fremstilling av terapeutisk aktive n-substituerte 3-piperidin- eller 3-pyridin-karboksylsyrederivater.
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen
DE69303234D1 (de) Behandlung von entzündlichen Darmerkrankungen
KR880007070A (ko) 백내장 치료용 약학 조성물
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
DE69201066D1 (de) Colominsäure und Produkte einer teilweisen Hydrolyse von Colominsäure zur Herstellung von Arzneimitteln zur Behandlung von Hepatitis, Nephritis und Arthritis.
DK0589741T3 (da) Anvendelse af en direkte thrombininhibitor til fremstilling af et lægemiddel med thrombolytisk aktivitet
DK0437025T3 (da) Midler indeholdende aldosereduktaseinhibitorer til behandling af ulcera
FI883730A0 (fi) Etrar och tioetrar med terapeutisk effekt, framstaellning av dessa och farmaceutiska sammansaettningar som innehaoller dem.
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties